摘要
Abstract
Objective To investigate the clinical efficacy of B cels of indolent lymphoma of bendamustine hydrochloride for injection in treatment of rituximab resistance in the.Methods 32 B cels in patients with indolent lymphoma were rituximab resistant cases,treated with bendamustine hydrochloride,observe the incidence of long- term and short-term curative effect,curative efect and adverse reaction analysis.Results 32 patients of recent curative effect of the total effective rate was 84.4%,the adverse reactions were bone marrow suppression,gastr- ointestinal reactions and infection.After 2 years of folow-up,the median remission duration of 10 months,because of a short folow-up period,1 patients because of disease progression and death.Conclusion The injection of bendam- ustine hydrochloride monotherapy rituximab resistant B cel indolent lymphoma remarkable curative effect.关键词
利妥昔单抗耐药/B细胞惰性淋巴瘤/盐酸苯达莫司汀Key words
Rituximab resistance/B cel indolent lymphoma/Bendamustine hydrochloride分类
医药卫生
